4.5 Article

Activation of tyrosine kinases by mutation of the gatekeeper threonine

Journal

NATURE STRUCTURAL & MOLECULAR BIOLOGY
Volume 15, Issue 10, Pages 1109-1118

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/nsmb.1486

Keywords

-

Funding

  1. US National Institutes of Health (NIH)
  2. NIH Roadmap for Medical Research
  3. Leukemia and Lymphoma Society
  4. Thomas Anthony Pappas Charitable Foundation
  5. Burroughs Wellcome Fund
  6. Life Science Research Foundation, Baltimore
  7. NIH [K99GM08009]

Ask authors/readers for more resources

Protein kinases targeted by small-molecule inhibitors develop resistance through mutation of the 'gatekeeper' threonine residue of the active site. Here we show that the gatekeeper mutation in the cellular forms of c-ABL, c-SRC, platelet-derived growth factor receptor-alpha and -beta, and epidermal growth factor receptor activates the kinase and promotes malignant transformation of BaF3 cells. Structural analysis reveals that a network of hydrophobic interactions-the hydrophobic spine-characteristic of the active kinase conformation is stabilized by the gatekeeper substitution. Substitution of glycine for the residues constituting the spine disrupts the hydrophobic connectivity and inactivates the kinase. Furthermore, a small-molecule inhibitor that maximizes complementarity with the dismantled spine (compound 14) inhibits the gatekeeper mutation of BCR-ABL-T315I. These results demonstrate that mutation of the gatekeeper threonine is a common mechanism of activation for tyrosine kinases and provide structural insights to guide the development of next-generation inhibitors.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available